BOSTON and LONDON, March 3, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision …
Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here BOSTON and LONDON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology …
Akari Therapeutics Joins Webull Corporate Connect Service Platform
Innovative targeted oncology company built on next-generation ADCs and a novel discovery engine Connect with the Company on Webull here BOSTON and LONDON …
[Read more...] about Akari Therapeutics Joins Webull Corporate Connect Service Platform
Akari Therapeutics Announces Key Leadership Appointments
Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec. 18, 2024 (GLOBE …
[Read more...] about Akari Therapeutics Announces Key Leadership Appointments
Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer
BOSTON and LONDON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) today announced the appointment of Torsten Hombeck, Ph.D. as Chief …
[Read more...] about Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer
